Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13380
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSavige, Judy Aen
dc.contributor.authorChang, Len
dc.contributor.authorSmith, C Len
dc.contributor.authorDuggan, J Cen
dc.date.accessioned2015-05-16T03:13:14Z
dc.date.available2015-05-16T03:13:14Z
dc.date.issued1993-01-01en
dc.identifier.citationLeukemia & Lymphoma; 9(1-2): 49-54en
dc.identifier.govdoc8477201en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13380en
dc.description.abstractA cutaneous or systemic vasculitis occurs in myelodysplasia as well as in myeloproliferative and lymphoproliferative disorders. The most common lesion is a leucocytoclastic vasculitis, with neurological or joint involvement occurring less often. The vasculitis may appear contemporaneously with or precede the clinical onset of the blood dyscrasia. Occasionally the lesions respond dramatically to the use of steroids but in general, patients with vasculitis have a worse prognosis than those with uncomplicated myelodysplasia. Vasculitis and myelodysplasia appear together too often for the association to be coincidental and the vasculitis in most cases cannot be attributed to intercurrent infections, therapeutic agents or a pre-existing rheumatological disorder. While autoantibodies are frequently present in myelodysplasia, and ANA and anti-neutrophil cytoplasm antibodies (ANCA) are found in other vasculitides, neither of these antibodies is associated with the vasculitis of myelodysplasia. There has however been one report of ANCA in Sweet's syndrome a non-vasculitic skin condition that also occurs in the myelodysplastic syndromes.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAlkylating Agents.adverse effectsen
dc.subject.otherAnemia, Refractory, with Excess of Blasts.epidemiologyen
dc.subject.otherAntigen-Antibody Complex.analysisen
dc.subject.otherAutoantibodies.immunologyen
dc.subject.otherCyclophosphamide.adverse effectsen
dc.subject.otherCytoplasm.immunologyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherIncidenceen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherMyelodysplastic Syndromes.chemically induced.complications.immunologyen
dc.subject.otherNeutrophils.immunologyen
dc.subject.otherPrognosisen
dc.subject.otherSweet Syndrome.immunologyen
dc.subject.otherVasculitis.etiology.immunologyen
dc.titleMyelodysplasia, vasculitis and anti-neutrophil cytoplasm antibodies.en
dc.typeJournal Articleen
dc.identifier.journaltitleLeukemia & lymphomaen
dc.identifier.affiliationUniversity Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.3109/10428199309148503en
dc.description.pages49-54en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8477201en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.